1. Home
  2. DYN vs QCRH Comparison

DYN vs QCRH Comparison

Compare DYN & QCRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYN
  • QCRH
  • Stock Information
  • Founded
  • DYN 1984
  • QCRH 1993
  • Country
  • DYN United States
  • QCRH United States
  • Employees
  • DYN N/A
  • QCRH N/A
  • Industry
  • DYN Medicinal Chemicals and Botanical Products
  • QCRH Major Banks
  • Sector
  • DYN Health Care
  • QCRH Finance
  • Exchange
  • DYN Nasdaq
  • QCRH Nasdaq
  • Market Cap
  • DYN 1.3B
  • QCRH 1.1B
  • IPO Year
  • DYN 2020
  • QCRH 1993
  • Fundamental
  • Price
  • DYN $14.70
  • QCRH $66.90
  • Analyst Decision
  • DYN Strong Buy
  • QCRH Buy
  • Analyst Count
  • DYN 13
  • QCRH 3
  • Target Price
  • DYN $45.92
  • QCRH $86.67
  • AVG Volume (30 Days)
  • DYN 2.0M
  • QCRH 75.2K
  • Earning Date
  • DYN 05-08-2025
  • QCRH 07-23-2025
  • Dividend Yield
  • DYN N/A
  • QCRH 0.36%
  • EPS Growth
  • DYN N/A
  • QCRH N/A
  • EPS
  • DYN N/A
  • QCRH 6.65
  • Revenue
  • DYN N/A
  • QCRH $324,275,000.00
  • Revenue This Year
  • DYN N/A
  • QCRH N/A
  • Revenue Next Year
  • DYN N/A
  • QCRH $7.10
  • P/E Ratio
  • DYN N/A
  • QCRH $9.98
  • Revenue Growth
  • DYN N/A
  • QCRH N/A
  • 52 Week Low
  • DYN $6.36
  • QCRH $54.75
  • 52 Week High
  • DYN $47.45
  • QCRH $96.08
  • Technical
  • Relative Strength Index (RSI)
  • DYN 72.20
  • QCRH 46.73
  • Support Level
  • DYN $13.14
  • QCRH $65.27
  • Resistance Level
  • DYN $12.34
  • QCRH $67.95
  • Average True Range (ATR)
  • DYN 0.79
  • QCRH 1.44
  • MACD
  • DYN 0.23
  • QCRH -0.29
  • Stochastic Oscillator
  • DYN 91.82
  • QCRH 27.72

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

About QCRH QCR Holdings Inc.

QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.

Share on Social Networks: